Shire Plc (SHP) will study its best-selling treatment for attention deficit hyperactivity disorder in preschool-age children as it seeks to expand the drug’s use.
from Content Keyword RSS http://ift.tt/1hMZ9ic http://ift.tt/eA8V8J
Advertisements